Invasive intraductal papillary mucinous neoplasm: predictors of survival and role of adjuvant therapy.
Adjuvant treatment for pancreatic adenocarcinoma has been shown to improve survival. An increasingly recognized 'subtype' of pancreatic adenocarcinoma is invasive intraductal papillary mucinous neoplasm (IPMN). It is unclear whether adjuvant treatment for invasive IPMN improves survival. This study aimed to determine the impact of adjuvant treatment in invasive IPMN.
Version: za2963e q8za8 q8zbf q8zcf q8zd9 q8ze5 q8zf4 q8zg5